SEC Tracker
Get the app

Enliven Therapeutics ELVN

Enliven appoints Kristine Ball to board

Form
8-K
Filed
Importance
Major
  1. Board increased to 8 directors
  2. Kristine Ball appointed as Class II director
  3. Annual cash compensation of $45,000 for director role
  4. Stock options valued at $650,000 granted

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Enliven Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.